european end-to-end CDMO company, pharma services

Unlocking the Future of Therapeutics

Further is Closer - What if the right CDMO partner was closer than you thought? €500,000 in services to take your biologic further.

Further → more

Many lifesaving biopharmaceuticals are suffering from a slump in venture funding. Novel recombinant protein based therapeutics, but also biosimilars are needed to fill the gaps in unmet patient needs.

At Mabion we understand how to advance promising biosimilars and novel biotherapeutics to the clinic and from there to patients. Unfortunately, many promising biopharmaceutical innovations spanning novel recombinant protein therapeutics to biosimilars are being held back in the current, limiting funding climate, depriving patients from access to advanced therapies. Yet the urgency to close gaps in unmet patient care has never been greater.

That is why we are launching the “Unlocking the Future of Therapeutics” competition a unique opportunity to support and accelerate biologics development and scale up for an oncology-targeted therapeutic.

We are offering €500,000 credit in development services to support an exceptional therapeutic project. This can be a novel therapeutic, but might also be a biosimilar drug which expands patients access to lifesaving care.

We have partnered with respected academic experts focused on cancer research to select the most promising candidate.

Nothing in life is to be feared; it is only to be understood.

Marie Skłodowska-Curie

Let’s grow together!

Let’s close the gap between scientific potential and patient outcomes. Apply now to accelerate your vision!

Welcome to the Competition – Entry Form

    The upper limit on the total size of an attached file to an e-mail message is 50 MB. Don’t worry, our BD specialists will take care of you. With larger files, send them straight to bd@mabion.eu

    Before submitting your application, read the terms and conditions.

    * These fields must be completed.

    Meet the Expert Jury

    Gestur Viðarsson, Prof.

    Principal Investigator at Sanquin and Professor of Immunoglobulin Biotherapeutics at the Utrecht Institute for Pharmaceutical Sciences

    Tadeusz Pietrucha, Prof.

    Head of the Medical Biotechnology Department at Medical University of Łódź

    Alicja Santos, PhD

    Chief Executive Officer of Polonium Foundation

    Julita Balcerek,
    PhD, MBA, IPMA C

    Chief Operating Officer of Mabion

    FAQ

    Mabion launched this contest to support promising oncology innovations that struggle to progress due to limited funding. With a history in drug development, Mabion seeks to help advance impactful therapies and promote Polish scientific excellence in medical research.
    The oncology pipeline is growing rapidly, yet funding remains a major barrier, especially for biologics. Mabion sees this as a critical moment to close that gap and accelerate novel therapies to patients.
    Mabion offers end-to-end biologics development and manufacturing under one roof, reducing risks and speeding timelines. Operating from a cost-effective EU base, Mabion combines regulatory excellence, personalized project management, and integrated quality systems.
    The winner receives €500,000 in service credits for biologics development, plus support with NDAs, proposal structuring, and business development. Mabion acts as a true partner, helping accelerate the project toward clinical readiness.
    The jury includes experts from academia and industry, chosen for their scientific and translational experience. They assess proposals based on impact, feasibility, and clinical potential, ensuring patient relevance and real-world viability.
    Mabion aims to be a strategic CDMO partner by investing in high-potential biotech programs. This contest supports that goal by strengthening its oncology focus and building long-term collaborations.
    Mabion hopes to speed up the development of new cancer treatments by equipping innovators with critical infrastructure. For biotech, it shows how CDMOs can drive innovation; for patients, it offers hope for faster access to breakthrough therapies.

    Further is closer. The breakthrough you need is closer than you think.

    Nigel Stapleton, VP of Business Development – Head of Europe at Mabion